Understanding and monitoring renal microvascular remodeling in CKD by super-resolution ultrasound

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00034268

Enrollment

Registered

2024-08-13

Start date

2022-10-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N18

Interventions

Group 1: Patients after kidney transplantation (eGFR >20ml/min): Contrast-Enhanced Ultrasound Group 2: Patients with chronic kidney disease (CKD): Contrast-Enhanced Ultrasound

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients after kidney transplantation with GFR = 20 ml/min (Study part A) 2. Patients with CKD with GFR = 20 ml/min (Study part B) 3. Written consent 4. Patients who are contractually capable and able to follow the requests of the study staff

Exclusion criteria

Exclusion criteria: 1. minors 2. allergy against ultrasound contrast agent or components sulfur hexafluoride, macrogol 4000, Colfoscerilstearat, 1-(1,2-Dipalmitoyl-3-sn-phosphatidyl)glycerol-Natriumsalt Palmitic acid 3. Left-right -shunt 4. signs of cardiovascular instability such as acute coronary syndrome, clinically instable ischemic heart disease, acute myocardial infarction, angina pectoris within 7 days prior, recent coronary intervention (PTA with or without stent), acute cardiac failure, cardiac insufficiency NYHA III or IV, severe arrhythmias 5. acute endocarditis 6. artificial heart valves 7. acute systemic inflammation and/or sepsis 8. coagulopathy or recent thromboembolic event 9. liver or kidney disease in end stage 10. severe pulmonary hypertension (pA pressure >90mmHg) 11. uncontrolled systemic hypertension 12. acute respiratory distress syndrome 13. clinically significant pulmonary disease including severe COPD 14. pregnancy 15. persons under official directive (prisoners, e.g.) 16. persons who are working for the sponsor or are dependent of the sponsor 17. alcohol or drug misuse 18. expected non-compliance

Design outcomes

Primary

Measure	Time frame
contrast-enhanced ultrasound images of the kidney are being post-processed to visualize the very small blood vessels (microcirculation)	—

Secondary

Measure	Time frame
Correlation of images with disease progression	—

Countries

Germany

Contacts

Public ContactSusanne Fleig

Uniklinik RWTH Aachen

sfleig@ukaachen.de+49 241 80 89531

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Aug 9, 2026